Looking for Abatacept found 19 matches
|
| Formulary |
BNF Category |
| |
Abatacept
(Orencia®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Adalimumab
(Humira® Amgevita®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Certolizumab Pegol
(Cimzia®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Etanercept
(Enbrel®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Golimumab
(Simponi®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Infliximab
(Remicade®)
(For use in line with NICE guidance)
|
Drugs affecting the immune response - 10.01.03
|
| |
Rituximab
(MabThera®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Tocilizumab
(RoActemra®)
|
Drugs affecting the immune response - 10.01.03
|
| |
Links Link to Drug Section  Link to document |
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
|
